Suven Life Sciences (Suven) has secured the grant of three product patents, two from USA and one from Mexico corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2025 and 2028.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (AND), Huntington's disease, Parkinson and Schizophrenia.
With these new patents, the company has a total of eleven granted patents from USA and twelve granted patents from Mexico. These granted patents are exclusive intellectual property of the company and are achieved through the internal discovery research efforts. The products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1692.40 |
Dr. Reddys Lab | 1108.30 |
Cipla | 1430.35 |
Lupin | 1984.00 |
Zydus Lifesciences | 857.25 |
View more.. |